宁波三星医疗电气股份有限公司 第六届董事会第二十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：601567 证券简称：三星医疗 公告编号：临 2025-063 宁波三星医疗电气股份有限公司（以下简称"公司"）于 2025 年 8 月 11 日以 书面方式发出召开第六届董事会第二十五次会议的通知，会议于 2025 年 8 月 21 日在公司会议室以现场结合通讯方式召开。本次会议应到董事 9 人，实到董事 9 人。会议由董事长沈国英女士主持，公司监事和其他高级管理人员列席了会议。 会议的召集和召开符合《中华人民共和国公司法》和《宁波三星医疗电气股份有 限公司章程》等法律、法规及规范性文件的有关规定。经与会董事认真审议并表 决，通过了以下议案，形成决议如下： 一、审议通过了关于 2025 年半年度报告及其摘要的议案 详见公司披露于上海证券交易所网站（www.sse.com.cn）的《三星医疗 2025 年半年度报告》及报告摘要。 表决结果：9 票赞成、0 票反对、0 票弃权。 该议案已经公司审计委员会审 ...

Dividend Distribution - The company plans to distribute a cash dividend of RMB 4.85 per 10 shares, totaling approximately RMB 678.76 million, which represents 55.20% of the net profit attributable to shareholders for the first half of 2025[6]. - The company aims to maintain a cash dividend payout ratio of no less than 45% annually from 2025 to 2027, sharing the development results with shareholders[85]. - The company maintained a cash dividend policy, emphasizing stable and continuous returns to shareholders[84]. - In the first half of 2025, the company approved a cash dividend distribution plan of 8.90 CNY (including tax) per 10 shares, totaling approximately 1.246 billion CNY, which accounts for 55.12% of the net profit attributable to shareholders for the fiscal year 2024[85]. - On August 21, 2025, the company proposed a cash dividend of 4.85 CNY (including tax) per 10 shares for the first half of 2025, estimated to distribute around 678.8 million CNY, representing 55.20% of the net profit attributable to shareholders for that period[86]. Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a year-over-year growth of 15%[16]. - The company's operating revenue for the first half of the year reached ¥7,972,213,807.13, representing a year-on-year increase of 13.93% compared to ¥6,997,465,533.74 in the same period last year[23]. - The total profit for the reporting period was ¥1,401,225,534.45, which is a 3.13% increase from ¥1,358,643,633.59 in the previous year[24]. - The net profit attributable to shareholders was ¥1,229,732,476.50, reflecting a growth of 6.93% compared to ¥1,150,008,819.85 in the same period last year[24]. - The company achieved a revenue of 7.972 billion yuan, a year-on-year increase of 13.93%, and a net profit attributable to shareholders of 1.230 billion yuan, up 6.93%[49]. Risk Management - The company has detailed potential risks in the management discussion and analysis section of the report[8]. - The report includes a forward-looking statement risk disclaimer, indicating that future plans do not constitute a commitment to investors[7]. - The company emphasizes the importance of reviewing the detailed risk descriptions provided in the report[8]. - The board of directors and management confirm the accuracy and completeness of the financial report, ensuring no significant omissions or misleading statements[3][5]. - There are no non-operational fund occupations by controlling shareholders or related parties[8]. Market Expansion and Strategy - The company is expanding its market presence by entering two new provinces, aiming for a 5% market share in these regions within the next year[16]. - A strategic acquisition of a local competitor was completed, which is anticipated to enhance the company's market position and increase revenue by 8%[16]. - The company has established partnerships with three new healthcare providers to expand its service offerings[16]. - The company is actively expanding its presence in key regions such as the Yangtze River Delta and the Pearl River Delta, focusing on high-quality rehabilitation services[46]. - The company is focusing on expanding its overseas market presence while enhancing its brand's international influence[81]. Research and Development - Research and development expenses increased by 25%, reflecting the company's commitment to innovation and technology advancement[16]. - The company invested 257 million RMB in R&D, accounting for 3.22% of consolidated operating revenue, to enhance its R&D capabilities and core competitiveness[83]. - The company has established four R&D centers and has been certified with CMMI V2.0 L5, indicating its strong research and innovation capabilities[59]. - The company has obtained 32 automation patents over the past three years, continuing to advance its "smart manufacturing" strategy[61]. - The company has developed a differentiated rehabilitation medical system, becoming a leading institution in rehabilitation medicine in China[64]. Financial Position and Assets - The company's total assets decreased by 5.02% to ¥23,246,567,450.35 from ¥24,476,486,586.93 at the end of the previous year[24]. - The company's total assets at the end of the reporting period were approximately ¥12.27 billion, indicating a stable asset base[150]. - The company's total liabilities decreased to ¥10,836,499,605.11 as of June 30, 2025, from ¥12,202,548,432.10 at the end of 2024, a decrease of about 11.2%[132]. - The total equity increased to ¥12,410,067,845.24 as of June 30, 2025, compared to ¥12,273,938,154.83 on December 31, 2024, reflecting an increase of approximately 1.1%[132]. - The company’s total liabilities and equity reflect a stable financial position, indicating ongoing operational capacity[168]. Corporate Governance - The board meeting was attended by all directors, ensuring collective responsibility for the report's content[4]. - The report has not been audited, and the management has declared the financial report's authenticity[5]. - The company has enhanced its information disclosure quality, actively reporting on orders, bids, and contracts to meet investor needs and regulatory requirements[86]. - The financial statements were approved by the board of directors on August 21, 2025, ensuring compliance with regulatory standards[166]. - The company adheres to the enterprise accounting standards, ensuring that financial statements accurately reflect its financial position and operating results[170]. Operational Efficiency - The company’s expense ratio for the first half of 2025 was 13.65%, a decrease of 3.92 percentage points year-on-year, reflecting improved operational efficiency[53]. - The company plans to enhance its supply chain efficiency, targeting a reduction in operational costs by 10% over the next fiscal year[16]. - The company is engaged in ongoing efforts to enhance its operational efficiency and market presence through strategic workforce integration[94]. - The company is enhancing its operational management through technological innovation and service model restructuring in response to deepening medical insurance payment reforms[39]. - The company has established a digital management system to mitigate operational risks associated with its expanding scale[81]. Compliance and Social Responsibility - The company is actively responding to national policies on common prosperity and corporate social responsibility[94]. - The company has included three subsidiaries in the list of enterprises required to disclose environmental information[93]. - The company has improved its ESG rating to AA, positioning it among the top in the industry, as part of its commitment to sustainable development[87]. - The company has made commitments regarding non-competition and profit forecasts, including a net profit target of no less than 47.5 million yuan for the 2023-2025 period[96]. - The company has outlined specific measures to ensure compliance with performance commitments and compensation obligations[97].

证券代码：601567 证券简称：三星医疗 公告编号：临 2025-067 宁波三星医疗电气股份有限公司 关于2025年半年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、利润分配预案内容 （一）利润分配预案的具体内容 截至2025年6月30日，宁波三星医疗电气股份有限公司（以下简称"公司"）母 公司期末未分配利润为人民币1,592,268,983.80元。经公司第六届董事会第二十五次会 议、第六届监事会第二十次会议审议通过，公司2025年半年度拟以实施权益分派股权 登记日登记的总股本（扣除回购专用账户的股份）为基数进行现金分红。本次利润分 配预案如下： 公司拟以本次实施权益分派股权登记日登记的总股本（扣除回购专用账户的股份） 为基数，向股东每10股派发现金红利（含税）4.85元。截至本公告披露日，公司总股 本为1,405,251,200股，扣除回购专用账户股份5,755,371股，公司可参与利润分配的总 股数为1,399,495,829股，以此计算预计合计派发现金红利约人民币678, ...

每经AI快讯，三星医疗（SH 601567，收盘价：24.66元）8月21日晚间发布公告称，公司第六届第二十 五次董事会会议于2025年8月21日在公司会议室以现场结合通讯方式召开。会议审议了《关于2025年半 年度报告及其摘要的议案》等文件。 2024年1至12月份，三星医疗的营业收入构成为：制造业占比76.16%，医疗业占比22.31%，其他业务占 比1.48%，金融业占比0.04%。 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 截至发稿，三星医疗市值为347亿元。 每经头条（nbdtoutiao）——最火游资不再是方新侠、章盟主、佛山无影脚？这名95后声名鹊起！ （记者 曾健辉） ...

Group 1 - Samsung Medical reported a revenue of approximately 7.972 billion yuan for the first half of 2025, representing a year-on-year increase of 13.93% [1] - The net profit attributable to shareholders of the listed company was approximately 1.23 billion yuan, showing a year-on-year increase of 6.93% [1] - Basic earnings per share were 0.87 yuan, reflecting a year-on-year increase of 7.41% [1] Group 2 - As of the report date, Samsung Medical's market capitalization stood at 34.7 billion yuan [2]

每经AI快讯，8月21日，三星医疗(601567.SH)发布2025年半年度报告，公司2025年上半年实现营业收入 79.72亿元，同比增长13.93%；实现归属于上市公司股东的净利润12.30亿元，同比增长6.93%。公司拟 向股东每10股派发现金红利4.85元（含税）。 ...

格隆汇8月21日丨三星医疗(601567.SH)公布半年度报告，报告期内，公司实现营业收入79.72亿元，同比 增长13.93%，实现归属于上市公司股东的净利润12.30亿元，同比增长6.93%，实现归属于上市公司股东 的扣除非经常性损益的净利润11.36亿元，同比增长5.34%。向股东每10股派发现金红利（含税）4.85 元。 ...

三星医疗公告，2025年上半年营业收入79.72亿元，同比增长13.93%。净利润12.3亿元，同比增长 6.93%。公司拟以本次实施权益分派股权登记日登记的总股本（扣除回购专用账户的股份）为基数，向 股东每10股派发现金红利（含税）4.85元。 ...

Group 1 - The core viewpoint of the articles highlights Samsung Medical's current stock performance, with a closing price of 25.19 yuan, an increase of 1.08%, and a rolling PE ratio of 14.84, marking a new low in 70 days, with a total market capitalization of 35.398 billion yuan [1][2] - The average PE ratio for the electric grid equipment industry is 39.42, with a median of 43.11, placing Samsung Medical at the 35th position within the industry [1] - As of March 31, 2025, Samsung Medical has 16,366 shareholders, a decrease of 898 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - For the first quarter of 2025, Samsung Medical reported an operating income of 3.631 billion yuan, a year-on-year increase of 20.03%, and a net profit of 489 million yuan, reflecting a year-on-year growth of 34.33%, with a sales gross margin of 28.90% [2] - The PE (TTM) for Samsung Medical is 14.84, while the static PE is 15.67, and the price-to-book ratio is 2.81, with a total market value of 35.398 billion yuan [2] - Comparatively, the industry average PE (TTM) is 39.42, with a static PE of 42.97 and a price-to-book ratio of 3.97, indicating that Samsung Medical's valuation is significantly lower than the industry average [2]

Group 1 - The high-pressure oxygen chamber concept declined by 0.68%, ranking among the top declines in concept sectors as of the market close on August 20 [1] - Within the high-pressure oxygen chamber sector, companies such as Innovate Medical, Yinkang Life, and Aoyang Health experienced significant declines, while Iron Construction Heavy Industry, Samsung Medical, and Dahu Co. saw increases of 4.29%, 1.08%, and 0.89% respectively [1] - The high-pressure oxygen chamber sector experienced a net outflow of 444 million yuan in main funds, with Innovate Medical leading the outflow at 537 million yuan [2] Group 2 - The top gainers in the market included the Tonghuashun Fruit Index at 3.70%, AI mobile phones at 2.77%, and MCU chips at 2.60%, while the high-pressure oxygen chamber concept was among the top decliners [2] - The main funds saw significant outflows from several stocks in the high-pressure oxygen chamber sector, with Innovate Medical, Aoyang Health, and Dahu Co. being the most affected [2] - Conversely, Iron Construction Heavy Industry, Samsung Medical, and Jinling Pharmaceutical attracted net inflows of main funds, indicating a shift in investor interest [2]